LYCOS RETRIEVER 
Cellegy Pharmaceuticals
built 179 days ago
Cellegy Pharmaceuticals is a specialty biopharmaceutical company engaged in the development and commercialization of prescription drugs with primary focus in the areas of gastroenterology, sexual dysfunction and women's health care. Cellegy has developed expertise in the use of nitroglycerin ointment and nitric oxide donors to address a number of serious conditions. Cellegesic(TM) ointment for the treatment of #### fissures and hemorrhoids is currently awaiting FDA protocol approval of a confirmatory Phase III clinical trial to treat the severe pain associated with chronic #### fissures. The Company is ... conducting clinical trials using Cellegesic to treat hemorrhoids. Other nitroglycerin based product candidates, in earlier clinical development, are targeting conditions including female sexual dysfunction, Raynaud's disease and prostate cancer.
Source:
Cellegy Pharmaceuticals is a biopharmaceutical company engaged in the development and commercialization of prescription drugs. The company offers prescription drugs to reduce transmission of sexually transmitted diseases. It primary operates in the US. The company is headquartered in Quakertown, Pennsylvania and employs five people.
Source:
QUAKERTOWN, Pa., Feb. 12 /PRNewswire-FirstCall/ -- Cellegy Pharmaceuticals, Inc. (OTC Bulletin Board: CLGY) today announced that it has entered into a definitive merger agreement providing for the acquisition of Cellegy by Adamis Pharmaceuticals Corporation. Adamis is a privately held specialty pharmaceuticals company that is engaged in the research, development and commercialization of products for the prevention of viral infections, including influenza. Adamis currently markets and sells a line of prescription products for a variety of allergy, respiratory disease and pediatric conditions, and ... owns a GMP certified independent contract packager of pharmaceutical and nutraceutical products. Adamis' chief executive officer, Dr. Dennis Carlo, is expected to become the chief executive officer of the combined company. Dr. Carlo is a veteran of the pharmaceutical and biotechnology industry, having previously served as CEO of publicly traded Immune Response Corporation, president of Telos Pharmaceuticals, and Vice President of Research and Development and Therapeutic manufacturing of Hybritech Inc. prior to its acquisition by Eli Lilly & Co.
Source:
Cellegy Pharmaceuticals Inc. reported earnings results for the third quarter and nine months ended September 30, 2006. For the quarter, the company reported net loss of $1.64 million or $0.05 per diluted share on total revenues were $0.172 million against net loss of $2.87 million or $0.10 per diluted share on total revenues were $1.74 million for the same period in 2005. For the nine months period, the company reported net loss of $5.34 million or $0.18 per diluted share on total revenues were $2.64 million against net loss of $3.17 million or $0.11 per diluted share on total revenues were $10.80 million for the same period in 2005. The decrease in revenues was primarily attributable to reduction in research and development salary expense, professional fees and clinical testing expenses.
Source:
Financial Communications Manager of Rohm & Haas Co. Mr. Williams has been Interim Chief Executive Officer of Cellegy Pharmaceuticals Inc., since January 2005. Mr. Williams founded Conner-Thoele Ltd. and serves as its President. Mr. Williams served as Vice Chairman, Strategic Planning of King Pharmaceuticals following the acquisition by King of Medco Research where he was Chairman. Prior to founding Conner-Thoele Limited, he served as Vice
Source:
"PDI was confident in its case against Cellegy, but decided to settle the litigation to avoid the time, cost and potential management distraction of a trial. PDI could receive $8.5 million with the possibility of additional upside potential," stated Beth R. Jacobson, Executive Vice President and General Counsel of PDI.
Source:
MORE ABOUT
Cellegy Pharmaceuticals